Artigo de periodico

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial (2017)

• Authors:
  • Ohman, E. Magnus
  • Roe, Matthew T.
  • Steg, P. Gabriel
  • James, Stefan K.
  • Povsic, Thomas J.
  • White, Jennifer
  • Rockhold, Frank
  • Plotnikov, Alexei
  • Mundl, Hardi
  • Strony, John
  • Sun, Xiang
  • Husted, Steen
  • Tendera, Michal
  • Montalescot, Gilles
  • Bahit, M. Cecilia
  • Ardissino, Diego
  • Bueno, Héctor
  • Claeys, Marc J.
  • Nicolau, Jose C.
  • Cornel, Jan H.
  • Goto, Shinya
  • Kiss, Róbert Gábor
  • Güray, Ümit
  • Park, Duk-Woo
  • Bode, Christoph
  • Welsh, Robert C.
  • Gibson, C. Michael
• Autor USP: NICOLAU, JOSÉ CARLOS - FM
• Unidade: FM
• DOI: 10.1016/S0140-6736(17)30751-1
• Subjects: FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO; ANTICOAGULANTES; DOENÇAS CARDIOVASCULARES
• Language: Inglês
• Imprenta:
  • Publisher place: London
  • Date published: 2017
• Source:
  • Título do periódico: Lancet
  • ISSN: 0140-6736
  • Volume/Número/Paginação/Ano: v. 389, n. 10081, p. 1799-1808, 2017

Informações sobre o DOI: 10.1016/S0140-6736(17)30751-1 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo NÃO é de acesso aberto
  
• Cor do Acesso Aberto: closed

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  OHMAN, E. Magnus et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, v. 389, n. 10081, p. 1799-1808, 2017Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(17)30751-1. Acesso em: 23 abr. 2024.

• APA

  Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J., et al. (2017). Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, 389( 10081), 1799-1808. doi:10.1016/S0140-6736(17)30751-1

• NLM

  Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1

• Vancouver

  Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial [Internet]. Lancet. 2017 ; 389( 10081): 1799-1808.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1016/S0140-6736(17)30751-1

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis TREAT trial
• Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial (vol 3, pg 391, 2018)
• Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
• Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
• Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial
• Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry
• Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54
• Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
• Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial
• Rationale and design of the long-Term rIsk, clinical manaGement, and healthcare Resource utilization of stable coronary artery dISease in post-myocardial infarction patients (TIGRIS) study